Biohaven shares rose nearly 30% after the FDA accepted a resubmitted application for Vyglxia, an experimental treatment for spinocerebellar ataxia previously rejected over efficacy concerns.
Biohaven Stock Soars Nearly 30% After FDA Accepts Resubmitted Application for Rare Disease Drug Vyglxia
